Analysts Expect Abeona Therapeutics Inc (ABEO) Will Announce Quarterly Sales of $240,000.00
Wall Street analysts forecast that Abeona Therapeutics Inc (NASDAQ:ABEO) will post $240,000.00 in sales for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Abeona Therapeutics’ earnings. The lowest sales estimate is $200,000.00 and the highest is $300,000.00. Abeona Therapeutics posted sales of $260,000.00 during the same quarter last year, which suggests a negative year over year growth rate of 7.7%. The company is expected to issue its next quarterly earnings report on Friday, March 30th.
On average, analysts expect that Abeona Therapeutics will report full year sales of $240,000.00 for the current year, with estimates ranging from $800,000.00 to $900,000.00. For the next fiscal year, analysts expect that the business will report sales of $1.21 million per share, with estimates ranging from $800,000.00 to $1.72 million. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that that provide coverage for Abeona Therapeutics.
Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings results on Wednesday, November 15th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.18) by $0.05. Abeona Therapeutics had a negative net margin of 2,946.58% and a negative return on equity of 27.69%. The company had revenue of $0.22 million during the quarter, compared to the consensus estimate of $0.22 million.
Abeona Therapeutics (ABEO) traded up $0.40 during midday trading on Thursday, reaching $15.65. The company’s stock had a trading volume of 780,059 shares, compared to its average volume of 750,183. The firm has a market cap of $732.03, a P/E ratio of -24.08 and a beta of 2.34. Abeona Therapeutics has a 12-month low of $4.50 and a 12-month high of $22.75.
Several institutional investors and hedge funds have recently modified their holdings of ABEO. State Street Corp acquired a new position in shares of Abeona Therapeutics in the 2nd quarter valued at about $1,900,000. Point72 Asset Management L.P. acquired a new position in shares of Abeona Therapeutics in the 3rd quarter valued at about $3,527,000. Northern Trust Corp increased its holdings in shares of Abeona Therapeutics by 406.3% in the 2nd quarter. Northern Trust Corp now owns 257,668 shares of the biopharmaceutical company’s stock valued at $1,649,000 after purchasing an additional 206,775 shares during the period. EAM Investors LLC acquired a new position in shares of Abeona Therapeutics in the 3rd quarter valued at about $2,509,000. Finally, Vanguard Group Inc. increased its holdings in shares of Abeona Therapeutics by 11.2% in the 2nd quarter. Vanguard Group Inc. now owns 1,081,670 shares of the biopharmaceutical company’s stock valued at $6,922,000 after purchasing an additional 108,730 shares during the period. Institutional investors own 41.97% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Analysts Expect Abeona Therapeutics Inc (ABEO) Will Announce Quarterly Sales of $240,000.00” was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another website, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this news story can be read at https://www.watchlistnews.com/analysts-expect-abeona-therapeutics-inc-abeo-will-announce-quarterly-sales-of-240000-00/1837989.html.
About Abeona Therapeutics
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.